SCHEMBL6776885

SCHEMBL6776885

COC(=O)c1ccc(C[C@@H](N)C(=O)O)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 8/20 0.68
LOXL2 Q9Y4K0 1/20 0.59
TPH1 P17752 3/20 0.58
PTGS1 P23219 2/20 0.58
ALPI P09923 1/20 0.58
PKM P14618 1/20 0.58
XIAP P98170 1/20 0.58
LNPEP Q9UIQ6 3/20 0.55
ERAP2 Q6P179 1/20 0.55
MAPT P10636 1/20 0.51
GRB2 P62993 1/20 0.50
PTPN1 P18031 1/20 0.50
CYP4A11 Q02928 1/20 0.50
KDM4E B2RXH2 1/20 0.50
USP2 O75604 1/20 0.50
EGFR P00533 1/20 0.50
LCK P06239 1/20 0.50
FYN P06241 1/20 0.50
ADORA3 P0DMS8 1/20 0.50
ALOX15 P16050 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1768596 1.00 SLC7A5 (0.68) SLC7A5LOXL2TPH1PTGS1ALPI
SCHEMBL1768600 1.00 SLC7A5 (0.68) SLC7A5LOXL2TPH1PTGS1ALPI
Tyrosine SCHEMBL10321534 0.94 SLC7A5 (0.71) SLC7A5LOXL2TPH1PTGS1ALPI
SCHEMBL1769570 0.89 LNPEP (0.65) SLC7A5LNPEPMAPTITGB3ITGA2B
SCHEMBL1769574 0.89 LNPEP (0.65) SLC7A5LNPEPMAPTITGB3ITGA2B
SCHEMBL11907060 0.88 POLB (0.56) SLC7A5LOXL2TPH1LNPEPERAP2
SCHEMBL11907057 0.88 POLB (0.56) SLC7A5LOXL2TPH1LNPEPERAP2
SCHEMBL15019652 0.87 LOXL2 (0.59) SLC7A5LOXL2LNPEPERAP2MAPT
SCHEMBL15019650 0.87 LOXL2 (0.59) SLC7A5LOXL2LNPEPERAP2MAPT
SCHEMBL2692900 0.84 LDHA (0.62) SLC7A5LOXL2MAPTCYP4A11TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6833382-B2 By muta-synthesis using a mutated micro-organism to influence the biosynthesis of at least one of the precursors of group B streptogramines; mutant strain employed is preferably derived from the strain S. pristinaespiralis SP92 AVENTIS PHARMA S.A. (FR) 2004-12-21 US disclosed
US-20020142947-A1 STREPTOGRAMINS AND METHOD FOR PREPARING SAME BY MUTASYNTHESIS AVENTIS PHARMA, S.A. 2002-10-03 US disclosed
US-6352839-B1 PREPARING VIRGINIAMYCINS FROM AN ENGINEERED MICROORGANISMS, HAVING THE ABILITY TO PREVENT BIOSYNTHESIS OF THE PRECURSOR ANTIBIOTIC; THE MICROORGANISM IS CULTURED IN THE PRESENCE OF A SECOND PRECURSOR AND THE STREPTOGRAMIN ANALOG IS RECOVERED AVENTIS PHARMA S.A. (FR) 2002-03-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020142947-A1 STREPTOGRAMINS AND METHOD FOR PREPARING SAME BY MUTASYNTHESIS EMG1, FBL, SMS SLC7A5 846/4885LOXL2 3426/4885TPH1 1383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.